INTELLIGENT BIO SOLUTIONS INC. (INBS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.63%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 4.63% | Share-based compensation / revenue. Period ending 2026-06-30. $195.21K ÷ $4.22M × 100 ≈ 4.63% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 4.22M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 195.21K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -12.61M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.22M | $195.21K | $-12.61M | (m) | (m) | 4.63% | (m) | (m) |
| 2026-03-31 | (m) | $3.91M | $109.78K | $-11.71M | (m) | (m) | 2.81% | (m) | (m) |
| 2025-12-31 | (m) | $3.58M | $97.58K | $-11.29M | (m) | (m) | 2.72% | (m) | (m) |
| 2025-09-30 | (m) | $3.29M | $48.00K | $-10.92M | (m) | (m) | 1.46% | (m) | (m) |
| 2025-06-30 | (m) | $3.05M | $238.04K | $-10.64M | (m) | (m) | 7.80% | (m) | (m) |
| 2025-03-31 | (m) | $2.94M | $238.24K | $-10.35M | (m) | (m) | 8.11% | (m) | (m) |
| 2024-12-31 | (m) | $3.03M | $444.54K | $-10.76M | (m) | (m) | 14.66% | (m) | (m) |
| 2024-09-30 | (m) | $3.19M | (m) | $-10.48M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.11M | $230.50K | $-10.28M | (m) | (m) | 7.41% | (m) | (m) |
| 2024-03-31 | (m) | $2.83M | $218.31K | $-10.17M | (m) | (m) | 7.72% | (m) | (m) |
| 2023-12-31 | (m) | $2.46M | (m) | $-13.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.74M | (m) | $-13.90M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.26M | $260.00K | $-12.60M | (m) | (m) | 20.69% | (m) | (m) |
| 2023-03-31 | (m) | $880.59K | (m) | $-11.98M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $616.03K | (m) | $-6.78M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $748.47K | (m) | $-8.12M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $437.15K | (m) | $-8.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.98M | (m) | $-7.10M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.82M | (m) | $-8.90M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $-6.35M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.98M | (m) | $-5.57M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $188.74K | (m) | $-2.86M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |